1-215993095-C-T
Variant summary
Our verdict is Uncertain significance. Variant got -2 ACMG points: 2P and 4B. PM3_SupportingBS1PP4
This summary comes from the ClinGen Evidence Repository: The c.6730G>A (p.Val2244Met) variant in USH2A is a missense variant predicted to cause a substitution of valine by methionine at amino acid 2244. The filtering allele frequency (the lower threshold of the 95% CI of 312/91082) of the c.6730G>A (p.Val2244Met) is 0.3112% for South Asian chromosomes by gnomAD v4.1.0, which meets the ClinGen Hearing Loss VCEP threshold (≥0.003) for BS1. The computational predictor REVEL gives a score of 0.28, which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. This variant has been detected in at least one individual with Usher syndrome. This individual was compound heterozygous for the variant and a pathogenic or likely pathogenic variant with phase unknown (p.Leu4567Profs*16; PMID:27460420) (PM3_Supporting). At least one patient with this variant displayed retinitis pigmentosa and sensorineural bilateral hearing loss, which is highly specific for Usher syndrome (PP4; PMID:27460420). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Usher syndrome, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP (BS1, PM3_Supporting, PP4; Version 2; 5/15/24). LINK:https://erepo.genome.network/evrepo/ui/classification/CA179542/MONDO:0019501/005
Frequency
Consequence
NM_206933.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.6730G>A | p.Val2244Met | missense_variant | 35/72 | ENST00000307340.8 | NP_996816.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.6730G>A | p.Val2244Met | missense_variant | 35/72 | 1 | NM_206933.4 | ENSP00000305941.3 | ||
USH2A | ENST00000674083.1 | c.6730G>A | p.Val2244Met | missense_variant | 35/73 | ENSP00000501296.1 |
Frequencies
GnomAD3 genomes AF: 0.000131 AC: 20AN: 152150Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.000506 AC: 127AN: 251106Hom.: 1 AF XY: 0.000634 AC XY: 86AN XY: 135690
GnomAD4 exome AF: 0.000228 AC: 333AN: 1461798Hom.: 1 Cov.: 31 AF XY: 0.000308 AC XY: 224AN XY: 727196
GnomAD4 genome AF: 0.000131 AC: 20AN: 152268Hom.: 1 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74424
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | - - |
Usher syndrome Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | research | SN ONGC Dept of Genetics and Molecular biology Vision Research Foundation | Dec 31, 2022 | - - |
Uncertain significance, reviewed by expert panel | curation | ClinGen Hearing Loss Variant Curation Expert Panel | Jun 28, 2024 | The c.6730G>A (p.Val2244Met) variant in USH2A is a missense variant predicted to cause a substitution of valine by methionine at amino acid 2244. The filtering allele frequency (the lower threshold of the 95% CI of 312/91082) of the c.6730G>A (p.Val2244Met) is 0.3112% for South Asian chromosomes by gnomAD v4.1.0, which meets the ClinGen Hearing Loss VCEP threshold (≥0.003) for BS1. The computational predictor REVEL gives a score of 0.28, which is neither above nor below the thresholds predicting a damaging or benign impact on USH2A function. This variant has been detected in at least one individual with Usher syndrome. This individual was compound heterozygous for the variant and a pathogenic or likely pathogenic variant with phase unknown (p.Leu4567Profs*16; PMID: 27460420) (PM3_Supporting). At least one patient with this variant displayed retinitis pigmentosa and sensorineural bilateral hearing loss, which is highly specific for Usher syndrome (PP4; PMID: 27460420). In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Usher syndrome, based on the ACMG/AMP criteria applied, as specified by the ClinGen Hearing Loss VCEP (BS1, PM3_Supporting, PP4; Version 2; 5/15/24). - |
Usher syndrome type 2A;C3151138:Retinitis pigmentosa 39 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 04, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Mar 27, 2018 | - - |
Usher syndrome type 2A Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Oct 26, 2021 | A heterozygous missense variation in exon 35 of the USH2A gene that results in the amino acid substitution of Methionine for Valine at codon 2244 was detected. The observed variant c.6730G>A (p.Val2244Met) has a minor allele frequency of 0.1% and 0.006% in the 1000 genomes and gnomAD database respectively. The in silico prediction of the variant are probably damaging by PolyPhen-2 and damaging by SIFT and MutationTaster-2. The reference codon is conserved across species. The segregation analysis showed this variant to be of maternal origin. In summary, the variant meets our criteria to be classified as a variant of uncertain significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 19, 2013 | The Val2244Met variant in USH2A has been previously reported in one individual w ith hearing loss; however variants in other genes were also identified in this i ndividual and the authors of the study attributed a homozygous variant in anothe r gene for causing the hearing loss (Shearer 2013). Computational analyses (bioc hemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. In summary, additional information is needed to fully assess the clinical significance of th is variant. - |
Retinitis pigmentosa 39 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | This sequence change replaces valine with methionine at codon 2244 of the USH2A protein (p.Val2244Met). The valine residue is highly conserved and there is a small physicochemical difference between valine and methionine. This variant is present in population databases (rs550772689, ExAC 0.4%), and has an allele count higher than expected for a pathogenic variant (Yuya Kobayashi et al). This variant has been observed in an individual affected retinitis pigmentosa (Keren J Carss et al). This variant has been reported to the ClinVar database as Uncertain significance. The variant is predicted to be damaging by both SIFT and PolyPhen2. The residue is conserved across species. The amino acid change p.Val2244Met in USH2A is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as uncertaiin significance. - |
Retinal dystrophy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2022 | - - |
USH2A-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 11, 2024 | The USH2A c.6730G>A variant is predicted to result in the amino acid substitution p.Val2244Met. This variant has been reported in individuals with Usher syndrome type 2 (Supplementary Table 4, Bonnet et al. 2016. PubMed ID: 27460420; Table S2, Carss et al 2016. PubMed ID: 28041643). This variant is reported in 0.40% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Retinitis pigmentosa Uncertain:1
Uncertain significance, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | Jan 01, 2015 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at